<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://hdl.handle.net/10646/2781">
    <title>DSpace Community:</title>
    <link>https://hdl.handle.net/10646/2781</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://hdl.handle.net/10646/3515" />
        <rdf:li rdf:resource="https://hdl.handle.net/10646/3512" />
        <rdf:li rdf:resource="https://hdl.handle.net/10646/3509" />
        <rdf:li rdf:resource="https://hdl.handle.net/10646/3508" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-09T21:27:27Z</dc:date>
  </channel>
  <item rdf:about="https://hdl.handle.net/10646/3515">
    <title>Current treatment and future prospects for the management of acute coronary syndromes</title>
    <link>https://hdl.handle.net/10646/3515</link>
    <description>Title: Current treatment and future prospects for the management of acute coronary syndromes
Authors: Bhagat, K.
Abstract: The impact of ischaemic heart disease on the burden of cardiovascular disease continues to escalate worldwide. • although international statistics suggest a levelling off in Western world, in the less industrialised parts of the world the effects of this diases are only beginning to be documented, nonetheless, rapid advances have been made in the diagnosis and management of the acute coronary sydromes (the term which encompasses the protean clinical manifestations of the ischaemic process). The therapeutic strategies discussed in this article cover two broad subjects that have been found to be critical in the evolution of the disease:- i. interfering with the haemostatic balance by retarding the thrombotic process; ii. modifying local and systemic vasoconstricting stimuli.</description>
    <dc:date>1999-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="https://hdl.handle.net/10646/3512">
    <title>Oh no, not Nitric Oxide!</title>
    <link>https://hdl.handle.net/10646/3512</link>
    <description>Title: Oh no, not Nitric Oxide!
Authors: Bhagat, K.
Abstract: Nitric oxide (NO) is a unique, endogenous regulatory molecule that is involved in a wide variety of physiological processes in multiple organ systems. This simple gas functions as a cellular messenger in a broad range of biological activities that include blood pressure regulation, immunomodulation and neurotransmission. It has also been implicated in a number of homeostatic functions in the cardiovascular system: it is a significant determinant of basal vascular tone and, in addition is thought to regulate myocardial contractility and platelet aggregation. Dysregulation of NO mediated effects have been implicated in the pathogenesis of essential hypertension, atherosclerosis, and the hypotension associated with septic shock. This review will focus on these multiple effects of NO in the cardiovascular system.</description>
    <dc:date>1999-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="https://hdl.handle.net/10646/3509">
    <title>Pharmacogenomics: today, tomorrow and beyond</title>
    <link>https://hdl.handle.net/10646/3509</link>
    <description>Title: Pharmacogenomics: today, tomorrow and beyond
Authors: Bhagat, K.
Abstract: Pharmacogenomics is today’s hot topic in biotechnology. In 1996 the word did not even exist; now international pharmacogenomics meetings are held monthly, and articles appear weekly in scientific journals ind the popular press. In this Viewpoint article, we will discuss what pharmacogenomics is and elaborate on vhat the impact of pharmacogenomics will be on medical practice in the next few years and further in the future.</description>
    <dc:date>1999-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="https://hdl.handle.net/10646/3508">
    <title>Trends in cancer pain management</title>
    <link>https://hdl.handle.net/10646/3508</link>
    <description>Title: Trends in cancer pain management
Authors: Bhagat, K.; Chinyanga, H. M.
Abstract: Background: Pain is a prevalent symptom in cancer patients, affecting up to 50% of patients undergoing active cancer treatment and up to 90% of those with advanced disease. Although adequate relief can be achieved in the majority of cancer patients, pain is often treated inadequately in traditional settings and sometimes even under the management of more specialised units.&#xD;
In this review the authors use their experience and that of others to review the evaluation and diagnosis of pain syndromes and the principles of management. This is in keeping with increasing recognition by bodies such as the World Health Organization and other governmental agencies who have recognised the importance of pain management as part of routine cancer care. Conducting a comprehensive assessment, competently providing analgesic drugs, and communicating with the patient and family allow effective management of pain in the cancer patient</description>
    <dc:date>2000-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

